Audit: QRS - FLGR-242 for Muscle Growth
Audit conducted on 13/09/2026 16:31 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 85 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: at-a-glance vs Conclusion (l.485-489), protocol cells vs Therapeutic Protocol (l.344-352), gates vs Key Interactions & Contraindications (l.292-320), tiers vs Expected Benefits/Potential Risks, 12 markers and cadence vs the Monitoring Protocol table (l.431-455). No unsupported claim. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious ER phrasing is carried across: “No validated protocol exists”, “No defined dose”, “No established target”, “Never measured for FLGR-242”, “not with any follistatin-derived agent”. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening. Contraindication thresholds (platelets <100 x 10^9/L, INR >1.5, eGFR <30, Child-Pugh B/C, NYHA III/IV, MI within 90 days, under 25) are reproduced at ER severity. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Benefit- and Risk-Modifying Factors (ER l.181-193, l.275-287) are not surfaced anywhere; gates draw only from the ER Key Interactions & Contraindications section. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | Only “bimagrumab” appears, in time_2_sub and time_3_sub, for the same fat-mass and HbA1c facts the ER attributes to it (ER l.150-158). No PMIDs, NCT IDs, expert names or years. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attribution appears that is not in the ER for the same fact. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s sceptical, evidence-first register throughout. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert and data-driven while remaining decision-useful; the gates, targets and cadence give the reader the means to act. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Descriptive throughout; no imperative or clinician voice. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No advice-implying language; content is presented as observation and measurement. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommend”, “advise”, “should” or “must” anywhere in the document body. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronoun in the document; grep for you/your/yourself returns nothing. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language is used wherever the ER allows; retained clinical terms (apolipoprotein B, Child-Pugh, NYHA, telangiectasia) are load-bearing decision or marker names taken verbatim from the ER. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every span is a condensed phrase or one to two short sentences. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing addresses a risk-aware self-directed user: certification of batch, third-party testing, own-baseline targets. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Assumes willingness to run a 12-marker panel, DXA scans and dynamometry. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not pitched at the general population; assumes the user already intends to source and self-administer. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Weighting reflects the audience: the sourcing/purity risk and the mass-without-strength dissociation are surfaced prominently. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No occurrence of “anti-aging”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Route of administration is formal (“Subcutaneous, abdominal”, “Intramuscular delivery”, “injection-site reactions”). “Loose stools” in the lede is the ER’s own Conclusion wording (ER l.487). |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings present and unmodified: Protocol, Time to effect, Benefits, Risk & Side Effects, Monitoring, Qualitative Assessment, Contraindications, Key Interactions, Marker/Target/Why, and the Low/Speculative tier labels. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Diff of data-qrs-var names against [qrs_template] shows all 34 template variables present; the only extras are the repeatable marker_#* and qualitative_item# rows the template defines. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Line diff against [qrs_template] shows changes confined to the metadata block and to variable spans addressed by checklist items; CSS, structure, subline scaffolding and footer disclaimer are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | N/A — no source ER section that the QRS draws from is empty; the empty Benefits/Risks High and Medium tiers are governed by items 12.5 and 13.5 instead. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels are the ER bold labels verbatim (“No validated protocol exists”, “Circulated dose ranges”, “Route and site”); interaction labels keep the ER bold label head verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Marker names are verbatim from the ER table; time labels use ER wording (“skeletal muscle mass”, “fat mass”, “glucose handling”). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Unicode scan for emoji ranges returns no match; the ER’s green/red/yellow squares and the warning/circle qualifiers were correctly stripped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to the minimum the other items permit: gate items carry no trailing rationale, tier lists are bare noun phrases with all parentheticals stripped, and marker cells are single clauses. Nothing is padded or extended. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The metadata comment spans lines 2-14, immediately after <!doctype html> and before any other content. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on line 3, closing --- on line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; not echoed by any visible element. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; only duration: "00:04" is quoted, which is required because the value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: flgr_242_muscle_2026-0913-1304_Opus_ER.md |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.9.11 matches the version badge of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0913-1605, correct YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | Single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5 |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | Nickname plus version number, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename matches the actual file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Confirmed, as for 5.4. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | <title>FLGR-242 for Muscle Growth - Quick Reference Sheet</title>; canonical_topic needs no entity encoding. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | header_topic: FLGR-242 for Muscle Growth, matching the ER frontmatter canonical_topic. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | header_subline_date: 09/13/2026, the MM/DD/YYYY form of qrs_creation_date 2026-0913-1605. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | header_subline_model: Opus 5 |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only the title and the template subline; no badge, AKA line, version stamp or audit date. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the ER Conclusion (l.485-489): engineered follistatin fragment, no published human or animal data, vendor-sourced claims, class effects, supply impurity. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | Exactly 60 words, counted programmatically. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct Conclusion passage: l.485 (laboratory-made fragment, nothing published, claims from the seller), l.487 (mass without strength, cramping, loose stools, blood fat, nosebleeds), l.489 (supply impurity). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms or specialist classifications; LDL is rendered as “a blood fat linked to artery disease” and the compound as “a laboratory-made protein”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes, risk ratios or confidence intervals. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from the ER “Populations who should avoid FLGR-242” list (ER l.310-320). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All 9 ER contraindications are represented, one to one. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Nine <li> elements inside the [stop_items] span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | No trailing rationale, citation or dash clause on any item. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Thresholds and staging preserved: platelets below 100 x 10^9/L, INR above 1.5, eGFR below 30 mL/min/1.73 m^2, Child-Pugh Class B or C, NYHA Class III or IV, MI within 90 days, cancer within the past 5 years, age under 25. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | N/A — the ER Key Interactions & Contraindications section uses no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Correctly non-empty; the ER names nine populations that should avoid the intervention. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | N/A — the section is not left empty; 9 contraindications are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Derived from the ER Key Interactions & Contraindications bullet list (ER l.292-308). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All 9 ER interactions present; none duplicates a contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Nine <li> elements inside the [caution_items] span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mitigation sentences and mechanistic rationale from the ER bullets are stripped; only the label, drug examples and the Caution/Monitor verdict remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists preserved for every applicable item (warfarin/apixaban/rivaroxaban/clopidogrel; ibuprofen/naproxen/aspirin; semaglutide/tirzepatide; prednisone/dexamethasone; testosterone/nandrolone/oxandrolone; atorvastatin/rosuvastatin; creatine/epicatechin/ecdysteroids/urolithin A; fish oil/ginkgo/garlic/vitamin E/nattokinase). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | N/A — the ER Key Interactions & Contraindications section uses no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Correctly non-empty; the ER names nine interactions. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | N/A — the section is not left empty; 9 interactions are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Derived from the ER Therapeutic Protocol section (ER l.342-368). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Absence of a validated protocol, the circulated dose range and the route/site are the three actionable aspects; the remaining ER bullets are unmeasured or advisory background. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | N/A — the ER Therapeutic Protocol section supplies well over three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine protocol spans carry ER-derived content; no placeholder remains. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Skeletal muscle mass, fat mass and glucose handling are the three ER outcomes with an attached timeframe. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered as in the ER Low tier by benefit magnitude: lean mass (+3.3% to +16.4%), fat mass (-20.5%), HbA1c (-0.76 points). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | N/A — the ER supplies more than three time-to-effect aspects; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time spans carry ER-derived content. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | N/A — the ER provides time-to-effect information (Practical Considerations “Time to effect”, plus the 48-week fat-mass and HbA1c timeframes). |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Derived from the ER Expected Benefits section (ER l.122-176). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four variables present in the template order. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Bare noun phrases only; no magnitudes, agents or mechanisms. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | The ER heading qualifiers (“Conflicted”, “Not Central to Muscle Growth”) and all magnitude lines are stripped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | benefits_high and benefits_medium spans are emptied and set to display: none; no empty-state phrasing was substituted. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Derived from the ER Potential Risks & Side Effects section (ER l.196-270). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four variables present in the template order. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Bare noun phrases only; no risk ratios, confidence intervals or percentages. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | All magnitude lines and the “Conflicted” qualifier on Effects on Bone are stripped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | risks_high and risks_medium spans are emptied and set to display: none. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER Monitoring Protocol & Defining Success section (ER l.429-446). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 12 rows of the ER biomarker table are present, in ER order, with targets and rationale preserved. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Cadence reproduces the ER narrative schedule (ER l.431): baseline, 2 weeks, 6 weeks, 12 weeks, 6 months, then every 3-6 months. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER qualitative marker list (ER l.448-455). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All 6 qualitative markers present and verbatim. |
Issues 13/09/2026 16:31
Pass rate 100.00%. No issues found.
Issues 13/09/2026 16:23
- 1.3 — Nosebleed scope qualifier dropped: [at_a_glance] (QRS lines 436–437) states that related compounds “bring cramping, loose stools, a rise in a blood fat linked to artery disease, and nosebleeds”, while the ER Conclusion (line 487) restricts the nosebleed signal to “the broadest-acting versions” — a qualifier that matters because FLGR-242 is marketed as more selective.
Fixes 13/09/2026 16:23
- 1.3 — Nosebleed scope qualifier restored: [at_a_glance] now reads “and nosebleeds with the broadest-acting versions” instead of the unqualified “and nosebleeds”, matching the ER Conclusion’s scoping of that signal; “No published study describes” was also aligned to the ER’s own “Nothing published describes”, and “the body’s own brake” shortened to “the body’s brake”, keeping the passage at 60 words.
Issues 13/09/2026 16:16
- 12.3 / 12.4 — Conflicted qualifier kept in benefits: [benefits_low] reads “improved physical function (conflicted)”, preserving a parenthetical qualifier that 12.4 requires to be stripped; the equivalent “⚠️ Conflicted” marker on the ER’s “Effects on Bone” was correctly dropped from [risks_speculative], making the treatment inconsistent as well.
Fixes 13/09/2026 16:16
- 12.3 / 12.4 — Conflicted qualifier stripped from benefits: Changed [benefits_low] from “improved physical function (conflicted)” to “improved physical function”, removing the parenthetical qualifier and matching how the ER’s “⚠️ Conflicted” marker was already handled in [risks_speculative].
Issues 13/09/2026 16:11
- 1.3 — Conflicted benefit stated unqualified: [benefits_low] (line 549) lists “improved physical function” with no conflict marker, whereas the ER grades it “⚠️ Conflicted” and concludes “Net reading: size increases, function usually does not” (ER line 144); the QRS’s own At-A-Glance states the opposite, “add muscle tissue but not strength” (line 435).
Fixes 13/09/2026 16:11
- 1.3 — Conflicted benefit now flagged: Changed the Benefits
Lowtier entry from “improved physical function” to “improved physical function (conflicted)”, carrying over the ER’s own “⚠️ Conflicted” status in plain text so the card no longer contradicts the At-A-Glance statement that related compounds “add muscle tissue but not strength”.